| Name | Title | Contact Details |
|---|
MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).
Make a difference—in your life and in the world—with a rewarding career at Gillette Children`s Specialty Healthcare. Gillette is a Twin Cities Top Workplace and a National Top Workplace. We offer competitive pay, a strong benefits package and flexible schedules. Plus we give employees something that sets us apart: a chance to take part in our mission. Come to work for Gillette, and you`ll improve the lives of countless children and adults who have disabilities or complex medical conditions. Each year, we see more patients and add more services. That growth enabled us to increase our workforce by more than 30 percent during the past five years. As we continue expanding, you`ll have many chances to learn new skills and advance your career. You`ll also collaborate with teams of caring professionals who are committed to making the world a better place.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.
Continuing Ed Courses is a Poway, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Advanced Biomedical Research is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.